Semaglutide and Cardiovascular Risks

The FDA requires manufacturers to assess the cardiovascular risk of all new therapies for type 2 diabetes. Semaglutide, a glucagon like peptide-1 analogue, lowers blood glucose, but does it increase cardiovascular risk? New research findings are summarized in a short video.capture-decran-2016-11-13-a-15-54-59

 

More findings in

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators*

N Engl J Med 2016; 375:1834-1844November 10, 2016DOI: 10.1056/NEJMoa1607141

http://www.nejm.org/do/10.1056/NEJMdo005100/full/?query=featured_home#.WCh-dYKfY0k.link

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: